NasdaqGS - Delayed Quote USD

Opthea Limited (OPT)

3.4000 -0.0200 (-0.58%)
At close: April 18 at 4:00 PM EDT
3.5900 +0.19 (+5.59%)
After hours: April 18 at 4:16 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. Founder, Chief Innovation Officer & Executive Director 599.73k -- 1975
Ms. Judith J. Robertson B.A., M.B.A. Chief Commercial Officer 588.59k -- 1961
Ms. Karen Adams CPA VP of Finance & Company Secretary 305.14k -- 1972
Dr. Frederic Guerard M.S., Pharm.D. Chief Executive Officer -- -- 1973
Mr. Peter F. Lang M.B.A. Chief Financial Officer -- -- 1973
Ms. Sarika Gulhar Ph.D. Executive Director of Human Resources -- -- --
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Development 128.19k -- 1965
Mr. Bruno Gagnon BPHARM, M.Sc. Senior Vice President of Global Clinical Operations -- -- 1969
Dr. Kenneth Sall Chief Medical Officer -- -- --
Dr. Fang Li Ph.D. Senior Vice President of Regulatory Affairs -- -- --

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399 https://opthea.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
24

Description

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Corporate Governance

Opthea Limited’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 10; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

OCS Oculis Holding AG
11.78
-2.16%
 
ANEB Anebulo Pharmaceuticals, Inc.
2.8500
-1.38%
 
ABVX ABIVAX Société Anonyme
15.11
+1.55%
 
PRTC PureTech Health plc
26.94
-0.31%
 
ANL Adlai Nortye Ltd.
10.65
+8.12%
 
DYAI Dyadic International, Inc.
1.5900
-5.36%
 
TRDA Entrada Therapeutics, Inc.
11.91
-2.54%
 
ICCC ImmuCell Corporation
5.05
0.00%
 
LENZ LENZ Therapeutics, Inc.
17.49
-1.19%
 
MEB.F MedinCell S.A.
10.78
-1.64%